ArticleNature cardiovascular research2024
Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.
Abstract read
In one paragraph
Article in Nature cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Immunophenotypic Assessment of Natural Killer Cell Degranulation and Monocyte Function from Cryopreserved Peripheral Blood Mononuclear Cells.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Article
- CD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis.International journal of molecular sciences · 2026Review
- Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.Haematologica · 2026Article
- Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?Haematologica · 2026Article
- Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy.Journal of cardiovascular development and disease · 2026Review
- 7-O-methylpunctatin is a potential inhibitor of human arachidonate 5-lipoxygenase: molecular and structural insights into anti-atherosclerosis therapeutics.Molecular diversity · 2026Article
- The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.Journal of internal medicine · 2026Review
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- The interplay between loneliness, cortisol, and NK cell function: The role of cortisol in NK cell dysfunction.Psychoneuroendocrinology · 2026Article
- Immune-Checkpoint-Inhibitor-Related Cardiovascular Toxicities in Cancer: A Mechanistic Review of Molecular Pathways with AI-Assisted Literature Clustering.International journal of molecular sciences · 2026Review
- B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts.Immunological reviews · 2026Review
- Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors.Cancer research communications · 2026Article
- Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.Cell reports. Medicine · 2026Article
- Lung cancer across borders: From molecular epidemiology to precision treatment strategies.Therapeutic advances in medical oncology · 2026Article
- Molecular basis of coronary artery disease-malignancy comorbidity: inflammation, immunometabolism, thrombosis, and cardio-oncology translation.Frontiers in immunology · 2026Review
- Mapping the patient pathway for ICI cardiac toxicities: a single-centre case series with clinical practice insights.The British journal of cardiology · 2026Article
- Inactivation of interleukin-15 reduces spontaneous atherosclerosis inFrontiers in physiology · 2026Article
- Bacterial tryptophan metabolites in cancer and atherosclerosis: insights for a role in immune checkpoint inhibition.Essays in biochemistry · 2025Review
- Immune Checkpoint Restoration as a Therapeutic Strategy to Halt Diabetes-Driven Atherosclerosis.Biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
José Gabriel Barcia Durán *NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-4764-5503
Dayasagar Das *NYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Michael GildeaNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Letizia AmadoriNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-1125-4631
Morgane GourvestNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Ravneet KaurNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-1278-2516
Natalia EberhardtNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-3309-4563
Panagiotis SmyrnisNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Burak CilhorozNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Swathy SajjaNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Karishma RahmanDivision of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-7675-9596
Dawn M FernandezDivision of Cardiology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Peter FariesDepartment of Surgery, Vascular Division, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Navneet NarulaDepartment of Pathology, New York University Grossman School of Medicine, New York University Langone Health, New York, NY, USA.
Rami VanguriDivision of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-8049-4829
Ira J GoldbergDivision of Endocrinology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-8701-2201
Edward A FisherNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-9802-143X
Jeffrey S BergerNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
Kathryn J MooreNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA. Kathryn.moore@nyulangone.org.ORCID http://orcid.org/0000-0003-2505-2547
Chiara GiannarelliNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA. chiara.giannarelli@nyulangone.org.ORCID http://orcid.org/0000-0003-2473-6058
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1MTriglycerides, Diabetes and Cardiovascular DiseaseP01HL151328 · NHLBI · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 2020 to 2026
$19.6MMolecular Regulation of Atherosclerosis Regression - RenewalR01HL084312 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI FISHER, EDWARD A · 2006 to 2024
$11.4MNon-coding RNA regulation of cholesterol homeostasis and atherosclerosisR35HL135799 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MOORE, KATHRYN J · 2017 to 2023
$6.7MDissecting the role of CD8+ T cells in atherosclerosisR01HL153712 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GIANNARELLI, CHIARA · 2020 to 2024
$3.3MMechanisms of atherosclerotic cardiovascular complications in COVID19R01HL165258 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GIANNARELLI, CHIARA · 2022 to 2025
$3.1MAmerican Heart Association (American Heart Association, Inc.) 20SFRN35210252American Heart Association (American Heart Association, Inc.) 23POST1029885American Heart Association (American Heart Association, Inc.) 965509NCI NIH HHS P30 CA016087NHLBI NIH HHS P01 HL151328NHLBI NIH HHS R01 HL084312NHLBI NIH HHS R01 HL153712NHLBI NIH HHS R01 HL165258NHLBI NIH HHS R35 HL135799U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL084312U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL153712U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL165258U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R35HL135799
Abstract
Immune checkpoint inhibitor (ICI) therapies can increase the risk of cardiovascular events in survivors of cancer by worsening atherosclerosis. Here we map the expression of immune checkpoints (ICs) within human carotid and coronary atherosclerotic plaques, revealing a network of immune cell interactions that ICI treatments can unintentionally target in arteries. We identify a population of mature, regulatory CCR7
Indexed as
Coronary Artery DiseaseImmune Checkpoint InhibitorsPlaque, AtheroscleroticAgedAntigens, CDAtherosclerosisCardiometabolic Risk FactorsCarotid Artery DiseasesCTLA-4 AntigenDiabetes Mellitus, Type 2FemaleHumansImmune Checkpoint ProteinsLymphocyte Activation Gene 3 ProteinMaleProgrammed Cell Death 1 ReceptorAntigens, CDCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsImmune Checkpoint ProteinsLag3 protein, humanLymphocyte Activation Gene 3 ProteinPDCD1 protein, humanProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.